11月20日，海利生物涨0.00%，成交额3461.02万元。两融数据显示，当日海利生物获融资买入额485.09 万元，融资偿还409.43万元，融资净买入75.66万元。截至11月20日，海利生物融资融券余额合计2.08亿 元。 融资方面，海利生物当日融资买入485.09万元。当前融资余额2.07亿元，占流通市值的4.64%，融资余 额低于近一年20%分位水平，处于低位。 融券方面，海利生物11月20日融券偿还2300.00股，融券卖出7600.00股，按当日收盘价计算，卖出金额 5.23万元；融券余量7.09万股，融券余额48.78万元，低于近一年50%分位水平，处于较低位。 责任编辑：小浪快报 资料显示，上海海利生物技术股份有限公司位于上海市黄浦区淮海中路138号805室，成立日期1981年7 月18日，上市日期2015年5月15日，公司主营业务涉及畜用、禽用动物疫苗的研发、生产和销售。主营 业务收入构成为：口腔71.34%，IVD28.61%，其他0.05%。 截至9月30日，海利生物股东户数3.38万，较上期增加7.16%；人均流通股19196股，较上期减少6.68%。 2025年1月-9月，海利生 ...

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Haili Biological, indicating a slight increase in stock price and a net financing outflow on October 22 [1] - On October 22, Haili Biological's stock price rose by 0.28%, with a trading volume of 31.17 million yuan. The financing buy-in amount was 4.60 million yuan, while the financing repayment was 5.52 million yuan, resulting in a net financing outflow of 0.92 million yuan [1] - As of October 22, the total margin balance for Haili Biological was 219 million yuan, with the financing balance accounting for 4.79% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low level of financing [1] Group 2 - As of June 30, Haili Biological had 31,500 shareholders, an increase of 0.14% from the previous period, while the average circulating shares per person decreased by 0.14% to 20,569 shares [2] - For the first half of 2025, Haili Biological reported an operating income of 110 million yuan, representing a year-on-year growth of 2.02%, and a net profit attributable to shareholders of 18.23 million yuan, which is a 20.56% increase year-on-year [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [3]